Patel et al. demonstrated in an NSCLC mouse model that estrogen increased VEGF and PDGF-BB levels, promoted pericyte coverage and myeloid recruitment, and, consequently, led to resistance against VEGF-targeted therapies [78]. Here, VEGFA is linked to non-small cell lung carcinoma.